Recently, a semisynthetic BA derivative INT-767 as a dual FXR and TGR5 agonist was developed [129], and it has been shown that this compound has the ability to inhibit liver injury and metabolic disorders. This evidence concerns the gene GPBAR1 and metabolic disease.